Overview of therapeutic options for epilepsy

Area of Science:

• Neurology
• Pediatrics
• Epileptology

Background:

• Tuberous Sclerosis Complex (TSC) epilepsy presents with diverse seizure types, including infantile spasms and focal seizures, significantly impacting cognitive and behavioral development.
• Early and effective seizure management is paramount for improving long-term outcomes in children with TSC.

Purpose of the Study:

• To review current and emerging therapeutic strategies for managing epilepsy in Tuberous Sclerosis Complex (TSC).
• To highlight specific treatment considerations and advancements for TSC-related seizures.

Main Methods:

• Review of current therapeutic options for TSC epilepsy, including first-line treatments, adjunctive therapies, and surgical interventions.
• Discussion of novel approaches such as early-onset vigabatrin treatment and mTOR inhibitors.

Main Results:

• Vigabatrin is a recommended first-line treatment for infantile spasms and early focal seizures in TSC.
• Cannabidiol and everolimus are approved adjunctive therapies for refractory seizures, alongside ketogenic diets.
• Surgical options, including stereotactic laser thermocoagulation, are essential for drug-resistant epilepsy, with potential for sequential interventions on epileptogenic tubers.
• Early initiation of vigabatrin treatment demonstrates efficacy in preventing or mitigating epilepsy development in TSC.

Conclusions:

• A multi-faceted approach combining pharmacotherapy, dietary interventions, and surgery is essential for optimal seizure control in TSC.
• Emerging treatments and early intervention strategies offer improved prospects for managing TSC epilepsy and its associated developmental challenges.